Consonance Capital Management’s Silence Therapeutics SLN Stock Holding History

Consonance Capital Management’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-634,270	Closed	-$7.52M	–	5
2022 Q2	$7.52M	Sell	634,270 -19,838	-3%	-$241K	31.7%	2
2022 Q1	$12.4M	Sell	654,108 -104,145	-14%	-$2.08M	21.08%	2
2021 Q4	$18.1M	Buy	758,253 +579,466	+324%	+$13.4M	11.82%	4
2021 Q3	$3.73M	Sell	178,787 -43,435	-20%	-$1.04M	2.04%	6
2021 Q2	$5.78M	Hold	222,222	–	–	0.7%	20
2021 Q1	$5.11M	Buy	+222,222	New	+$5.41M	0.54%	28

Other funds holding SLN

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

LOAME

Lombard Odier Asset Management (Europe) London, United Kingdom $1.85B AUM 27.05% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Consonance Capital Management's SLN Position: Q3 2022 in Review

Consonance Capital Management sold out of Silence Therapeutics (SLN) in Q3 2022, closing a stake of 634,270 shares — an estimated $7.52M sold.

Consonance Capital Management first reported a position in SLN in Q1 2021 and held it in 6 quarters. The position peaked at $18.1M in Q4 2021. 29 funds tracked by Wall St. Rank hold SLN as of Q3 2022.

Consonance Capital Management reported no remaining Silence Therapeutics position as of Q3 2022 after selling out during the quarter.
Consonance Capital Management sold 634,270 Silence Therapeutics shares in Q3 2022, an estimated $7.52M.
Consonance Capital Management first reported a position in Silence Therapeutics in Q1 2021 and held it in 6 quarters.
Consonance Capital Management's Silence Therapeutics position peaked at $18.1M in Q4 2021.
29 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2022.

Based on Consonance Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.